Anthem Biosciences · NSE: ANTHEM · BSE: 544449
Q1 FY26 results · Apr–Jun 2025
Anthem Biosciences reported revenue from operations of ₹540.21 crore and net profit of ₹135.79 crore for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 540.21 | — | — | — | — |
| Other income | 22.81 | — | — | — | — |
| Total income | 563.02 | — | — | — | — |
| Profit before tax | 186.25 | — | — | — | — |
| Net profit for the period | 135.79 | — | — | — | — |
| EPS, basic (₹) | 2.43 | — | — | — | — |
| Net margin (%) | 25.1 | — | — |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 538.01 | — | — | — | — |
| Other income | 27.73 | — | — | — | — |
| Total income | 565.74 | — | — | — | — |
| Profit before tax | 198.94 | — | — | — | — |
| Net profit for the period | 148.34 | — | — | — | — |
| EPS, basic (₹) | 2.65 | — | — | — | — |
| Net margin (%) | 27.6 | — | — |
Consolidated
- Filed with BSE
- 13 Aug 2025, 21:39 IST
- Board meeting
- 13 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Aug 2025, 21:39 IST
- Board meeting
- 13 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE